Abaxis Inc (ABAX) Files 10-K for the Fiscal Year Ended on March 31, 2018

Abaxis Inc (NASDAQ:ABAX) files its latest 10-K with SEC for the fiscal year ended on March 31, 2018. Abaxis Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Abaxis Inc has a market cap of $1.91 billion; its shares were traded at around $83.42 with a P/E ratio of 70.69 and P/S ratio of 8.17. The dividend yield of Abaxis Inc stocks is 0.73%. Abaxis Inc had annual average EBITDA growth of 11.10% over the past ten years. GuruFocus rated Abaxis Inc the business predictability rank of 4-star.

For the last quarter Abaxis Inc reported a revenue of $67.9 million, compared with the revenue of $58.20 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $244.7 million, an increase of 7.7% from last year. For the last five years Abaxis Inc had an average revenue growth rate of 7.7% a year.

The reported diluted earnings per share was $1.17 for the year, a decline of 18.8% from the previous year. Over the last five years Abaxis Inc had an EPS growth rate of 7% a year. The Abaxis Inc had a decent operating margin of 15.8%, compared with the operating margin of 19.58% a year before. The 10-year historical median operating margin of Abaxis Inc is 16.90%. The profitability rank of the company is 7 (out of 10).

At the end of the fiscal year, Abaxis Inc has the cash and cash equivalents of $46.3 million, compared with $91.3 million in the previous year. The long term debt was $0.18 million, compared with $0.28 million in the previous year. Abaxis Inc has a financial strength rank of 8 (out of 10).

At the current stock price of $83.42, Abaxis Inc is traded at 66% premium to its historical median P/S valuation band of $50.24. The P/S ratio of the stock is 8.17, while the historical median P/S ratio is 4.92. The intrinsic value of the stock is $19.32 a share, according to GuruFocus DCF Calculator. The stock gained 68.03% during the past 12 months.

Directors and Officers Recent Trades:

Chief Technology Officer Kenneth Aron sold 1,533 shares of ABAX stock on 05/22/2018 at the average price of $83.11. The price of the stock has increased by 0.37% since.Director Prithipal Singh sold 20,000 shares of ABAX stock on 05/18/2018 at the average price of $83.31. The price of the stock has increased by 0.13% since.Managing Director-Europe Achim Henkel sold 6,000 shares of ABAX stock on 05/08/2018 at the average price of $68.06. The price of the stock has increased by 22.57% since.

For the complete 20-year historical financial data of ABAX, click here.

Leave a Reply

Your email address will not be published. Required fields are marked *